394 related articles for article (PubMed ID: 9351532)
21. Therapeutic properties and safety of recombinant factor VIII and factor IX.
Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
23. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
Briët E; Mauser-Bunschoten EP
Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
[TBL] [Abstract][Full Text] [Related]
24. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
Hilfenhaus J; Weidmann E
Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
[TBL] [Abstract][Full Text] [Related]
25. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
26. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
[TBL] [Abstract][Full Text] [Related]
27. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
28. Human parvovirus PARV4 in clotting factor VIII concentrates.
Fryer JF; Hubbard AR; Baylis SA
Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
[TBL] [Abstract][Full Text] [Related]
29. Immunoaffinity purification of factor VIII.
Weinstein RE
Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
[TBL] [Abstract][Full Text] [Related]
30. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
Johnson AJ; Mathews RW; Fulton AJ
Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
[TBL] [Abstract][Full Text] [Related]
31. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
32. The choice of plasma-derived clotting factor concentrates.
Mannucci PM
Baillieres Clin Haematol; 1996 Jun; 9(2):273-90. PubMed ID: 8800505
[TBL] [Abstract][Full Text] [Related]
33. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of human viral disease transmission through plasma products.
Heldebrant CM; Friedman AE; Fedor EJ
Dev Biol Stand; 1987; 67():319-22. PubMed ID: 2440744
[TBL] [Abstract][Full Text] [Related]
35. Blood safety and the choice of anti-hemophilic factor concentrate.
Janco RL
Pediatr Blood Cancer; 2007 Jan; 48(1):117. PubMed ID: 17063470
[No Abstract] [Full Text] [Related]
36. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy in viral inactivation of the concentrates of factor VIII and IX by the solvent/detergent procedure. Evaluation in patients with hemophilia].
Guerois C; Parquet A; Vicariot M; Lecoeur FF; Maisonneuve P; Courouce AM; Dubois F; Laurian Y
Presse Med; 1991 Jun; 20(25):1163-6. PubMed ID: 1830653
[TBL] [Abstract][Full Text] [Related]
38. [Plasma concentrates of factor VIII. Where are we?].
Vicente V
Sangre (Barc); 1989 Feb; 34(1):1-3. PubMed ID: 2496481
[No Abstract] [Full Text] [Related]
39. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
Hilfenhaus J; Nowak T
Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
[TBL] [Abstract][Full Text] [Related]
40. [Gene therapy for hemophilia: feasible in principle but not yet clinically applicable].
van der Eb MM; Schagen FH; van Ormondt H; Hoeben RC
Ned Tijdschr Geneeskd; 1998 Apr; 142(15):840-4. PubMed ID: 9623157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]